AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-53. (Canceled)

54. (Currently Amended) A method of inhibiting rejection of grafted cells, tissue, or organ in a mammal in need thereof comprising administering to the mammal a dose, effective to inhibit graft rejection, of a composition comprising purified complexes, each complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, wherein the heat shock protein is a member of the hsp90 family of heat shock proteins, ~~and~~ wherein the composition is administered after the cells, tissue, or organ is grafted to the mammal, and wherein the amount of the complexes present in the composition is 100 μg or more.

55. (Currently Amended) A method of inhibiting rejection of grafted cells, tissue, or organ in a mammal in need thereof comprising administering to the mammal a dose, effective to inhibit graft rejection, of a composition comprising purified complexes, each complex consisting essentially of a heat shock protein non-covalently bound to a peptide, wherein the peptide is not an alloantigen of the grafted cells, tissue, or organ, and wherein the heat shock protein is a member of the hsp90 family of heat shock proteins, the method further comprising administering to the mammal a sample of cells or tissue obtained from the cells, tissue, or organ donor prior to administration of the composition, ~~and~~ wherein said composition is administered prior to the cells, tissue, or organ being grafted to the mammal, and wherein the amount of the complexes present in the composition is 100 μg or more.

56. (Canceled)

57. (Previously Presented) The method of claim 54 or 55, wherein the complexes are isolated from a healthy organ of the mammal, wherein said mammal is not experiencing graft rejection or an autoimmune response directed at said healthy organ.

58. (Previously Presented) The method of claim 54 or 55, wherein the heat shock protein is not an alloantigen of the grafted cells, tissue, or organ.

59. (Previously Presented) The method of claim 54 or 55, wherein the grafted cells, tissue, or organ is skin, liver, kidney, heart, bone marrow, pancreas, lung, cornea, cartilage, or cells derived therefrom.

60. (Previously Presented) The method of claim 59, wherein the grafted cells or tissue is skin or cells derived from skin.

61. (Previously Presented) The method of claim 54 or 55, wherein the heat shock protein is a mammalian heat shock protein.

62. (Previously Presented) The method of claim 54 or 55, wherein the heat shock protein is human heat shock protein.

63. (Previously Presented) The method of claim 54 or 55, wherein the heat shock protein is gp96.

64. (Previously Presented) The method of claim 54 or 55, wherein the heat shock protein is hsp90.

65. (Previously Presented) The method of claim 54 or 55, wherein the heat shock proteins of said complexes are a combination of gp96 and hsp90.

66. (Previously Presented) The method of claim 54 or 55, wherein the mammal is human.

67. (Previously Presented) The method of claim 58, wherein the mammal is human.

68. (Previously Presented) The method of claim 63, wherein the mammal is human.

69. (Previously Presented) The method of claim 54 or 55, wherein said composition comprises a purified population of complexes, each complex in said population consisting essentially of a heat shock protein non-covalently bound to a peptide, and wherein said population of complexes comprises different peptides.

70. (Currently Amended) The method of claim ~~56~~ 54 or 55, wherein the heat shock protein is gp96.

71. (Currently Amended) The method of claim ~~56~~ 54 or 55, wherein the mammal is human.

72. (New) The method of claim 54 or 55, wherein said administering is subcutaneous.

73. (New) The method of claim 54 or 55, wherein said administering is intradermal.